Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis
Prof Mendel E Singer, David C Kaelber, Maria J Antonelli
Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-218500
Table 1 Proportion of patients taking hydroxychloroquine: COVID-19 vs two control groups COVID-19 Influenza/ pneumonia/LRI CI for difference (COVID-19 vs I/P/LRI) Any outpatient visit CI for difference (COVID-19 vs OP) Age 18 and over No of patients, N 16 869 198 114 3 970 695 Lupus or RA on an immunosuppressant, N 159 2609 32 599 Hydroxychloroquine, % (N) 34.6% (55) 31.4% (819) (−4.4% to 10.8%) p=0.4290 32.7% (10 645) (−5.5% to 9.4%) p=0.6115 Age 18-64 No of patients, N 13 327 128 280 2 715 365 Lupus or RA on an immunosuppressant, N 121 1477 20 256 Hydroxychloroquine, % (N) 37.2% (45) 37.0% (547) (−8.8% to 9.1%) p=1.0000 36.9% (7473) (−8.3% to 8.9%) p=1.0000 I/P/LRI, influenza/pneumonia/other lower respiratory infection; LRI, lower respiratory infection; OP, outpatient; RA, rheumatoid arthritis.
References
Arshad, Kilgore, Chaudhry, Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis,
doi:10.1016/j.ijid.2020.06.099Bozzalla Cassione, Zanframundo, Biglia, COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-217717Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2012410Gendebien, Frenckell, Ribbens, Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-218244Magagnoli, Narendran, Pereira, Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, medRxiv,
doi:10.1016/j.medj.2020.06.001Rosenberg, Dufort, Udo, Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state, JAMA,
doi:10.1001/jama.2020.8630Tang, Cao, Han, Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial, BMJ
{ 'indexed': {'date-parts': [[2023, 9, 28]], 'date-time': '2023-09-28T09:51:24Z', 'timestamp': 1695894684039},
'reference-count': 10,
'publisher': 'BMJ',
'issue': '9',
'license': [ { 'start': { 'date-parts': [[2020, 8, 5]],
'date-time': '2020-08-05T00:00:00Z',
'timestamp': 1596585600000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://bmj.com/coronavirus/usage'}],
'content-domain': {'domain': ['bmj.com'], 'crossmark-restriction': True},
'published-print': {'date-parts': [[2022, 9]]},
'DOI': '10.1136/annrheumdis-2020-218500',
'type': 'journal-article',
'created': {'date-parts': [[2020, 8, 5]], 'date-time': '2020-08-05T21:20:37Z', 'timestamp': 1596662437000},
'page': 'e161-e161',
'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy',
'source': 'Crossref',
'is-referenced-by-count': 8,
'title': 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis',
'prefix': '10.1136',
'volume': '81',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-3331-3340',
'authenticated-orcid': False,
'given': 'Mendel E',
'family': 'Singer',
'sequence': 'first',
'affiliation': []},
{'given': 'David C', 'family': 'Kaelber', 'sequence': 'additional', 'affiliation': []},
{'given': 'Maria J', 'family': 'Antonelli', 'sequence': 'additional', 'affiliation': []}],
'member': '239',
'published-online': {'date-parts': [[2020, 8, 5]]},
'reference': [ { 'key': '2023092706101180000_81.9.e161.1',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/annrheumdis-2020-217480'},
{ 'key': '2023092706101180000_81.9.e161.2',
'doi-asserted-by': 'crossref',
'unstructured': 'Tang W , Cao Z , Han M , et al . Hydroxychloroquine in patients mainly '
'with mild to moderate COVID-19: an open-label, randomized, controlled '
'trial. BMJ 2020:369.',
'DOI': '10.1101/2020.04.10.20060558'},
{ 'key': '2023092706101180000_81.9.e161.3',
'doi-asserted-by': 'crossref',
'first-page': '2411',
'DOI': '10.1056/NEJMoa2012410',
'article-title': 'Observational study of hydroxychloroquine in hospitalized patients with '
'Covid-19',
'volume': '382',
'author': 'Geleris',
'year': '2020',
'journal-title': 'N Engl J Med'},
{ 'key': '2023092706101180000_81.9.e161.4',
'doi-asserted-by': 'crossref',
'DOI': '10.1001/jama.2020.8630',
'article-title': 'Association of treatment with hydroxychloroquine or azithromycin with '
'in-hospital mortality in patients with COVID-19 in New York state',
'author': 'Rosenberg',
'year': '2020',
'journal-title': 'JAMA'},
{ 'key': '2023092706101180000_81.9.e161.5',
'article-title': 'Outcomes of hydroxychloroquine usage in United States veterans '
'hospitalized with Covid-19',
'author': 'Magagnoli',
'year': '2020',
'journal-title': 'medRxiv'},
{ 'key': '2023092706101180000_81.9.e161.6',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ijid.2020.06.099'},
{ 'key': '2023092706101180000_81.9.e161.7',
'unstructured': 'FDA approved drug products: hydroxychloroquine oral tablets. Available: '
'https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf '
'[Accessed 8 Jul 2020].'},
{ 'key': '2023092706101180000_81.9.e161.8',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/annrheumdis-2020-217717'},
{ 'key': '2023092706101180000_81.9.e161.9',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/annrheumdis-2020-218244'},
{ 'key': '2023092706101180000_81.9.e161.10',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/annrheumdis-2020-218068'}],
'container-title': 'Annals of the Rheumatic Diseases',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2020-218500',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 9, 27]],
'date-time': '2023-09-27T13:11:16Z',
'timestamp': 1695820276000},
'score': 1,
'resource': {'primary': {'URL': 'https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2020-218500'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2020, 8, 5]]},
'references-count': 10,
'journal-issue': { 'issue': '9',
'published-online': {'date-parts': [[2022, 8, 11]]},
'published-print': {'date-parts': [[2022, 9]]}},
'alternative-id': ['10.1136/annrheumdis-2020-218500'],
'URL': 'http://dx.doi.org/10.1136/annrheumdis-2020-218500',
'relation': {},
'ISSN': ['0003-4967', '1468-2060'],
'subject': [ 'General Biochemistry, Genetics and Molecular Biology', 'Immunology', 'Immunology and Allergy',
'Rheumatology'],
'container-title-short': 'Ann Rheum Dis',
'published': {'date-parts': [[2020, 8, 5]]}}
